[32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma.
In an initial safety study, phosphorus-32 (as diphosphonate) was administered intravenously to five patients with painful bone metastases from prostatic carcinoma; two patients received 9 mCi and three were given 3 mCi. Hematological, biochemical, ECG, x-ray, bone-scan data, and clinical observation, were followed for 2 mo. At both dose levels, bone-marrow depression was noted. One of the patients, who received 9 mCi, had only a slight dip in the levels of circulating white blood cells and platelets. The other 9-mCi patient was the only one with discrete metastases by bone scan; he had bone-marrow depression, from which he recovered, and was the only one of the five who had relief of bone pain.
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011471:Prostatic Neoplasms; D011879:Radiotherapy Dosage
D010761:Phosphorus Radioisotopes; D012968:Etidronic Acid